Lesson plan

LE135

LE135 is a drug which acts as a selective retinoic acid receptor β (RARβ) antagonist. It was developed in the 1990s and has been widely used for research into the function of RARβ especially its roles in cell differentiation during growth, tissue repair and embryonic development, regulation of immune system function, and development of certain forms of cancer. However, it has also been shown to act as a potent activator of the cation channels TRPV1 and TRPA1, which means caution must be applied when interpreting results which assume that it is only acting by blocking RARβ.

Back to article

Article summary

LE135 is a drug which acts as a selective retinoic acid receptor β (RARβ) antagonist. It was developed in the 1990s and has been widely used for research into the function of RARβ especially its roles in cell differentiation during growth, tissue repair and embryonic development, regulation of immune system function, and development of certain forms of cancer. However, it has also been shown to act as a potent activator of the cation channels TRPV1 and TRPA1, which means caution must be applied when interpreting results which assume that it is only acting by blocking RARβ.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.